CytomX Therapeutics (CTMX) Other financing activities (2015 - 2026)

CytomX Therapeutics' Other financing activities history runs 12 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (up 3931.03% YoY) and the FY2025 annual result came in at $811000.0, changed N/A from the prior year.
• Other financing activities was $5.9 million for Q1 2026 at CytomX Therapeutics, up from $381000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $29.4 million in Q3 2023 and bottomed at -$458000.0 in Q3 2022.
• A 5-year average of $3.0 million and a median of $254500.0 in 2024 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities slumped 540.38% — and 2023, when it surged 6508.73%.
• CytomX Therapeutics' Other financing activities stood at -$458000.0 in 2022, then jumped by 6508.73% to $29.4 million in 2023, then tumbled by 101.46% to -$430000.0 in 2024, then surged by 188.6% to $381000.0 in 2025, then soared by 1436.75% to $5.9 million in 2026.
• Business Quant data shows CTMX's Other financing activities at $5.9 million in Q1 2026, $381000.0 in Q4 2025, and $253000.0 in Q3 2025.